Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer - Trial NCT06341309
Access comprehensive clinical trial information for NCT06341309 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by West China Hospital and is currently Not yet recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
West China Hospital
Timeline & Enrollment
Phase 1/2
Apr 01, 2024
Aug 01, 2026
Primary Outcome
Progression free survival -1
Summary
To evaluate the progression-free survival (PFS1), objective response rate (ORR), disease
 control rate (DCR), progression-free survival from first-line treatment initiation (PFS2),
 overall survival (OS), and safety of irinotecan liposome combined with bevacizumab in
 patients with advanced metastatic colorectal cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06341309
Non-Device Trial